In:
Klinische Pädiatrie, Georg Thieme Verlag KG, Vol. 229, No. 03 ( 2017-05), p. 147-167
Abstract:
The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Most low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise patient characterization at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials.
Type of Medium:
Online Resource
ISSN:
0300-8630
,
1439-3824
DOI:
10.1055/s-0043-103086
Language:
English
Publisher:
Georg Thieme Verlag KG
Publication Date:
2017
detail.hit.zdb_id:
2039110-9